Gtx Inc.'s blowup in two Phase III trials with enobosarm for muscle wasting in non-small-cell lung cancer patients (NSCLC) left the company with apparently dicey odds for approval in the U.S., where the FDA has granted the selective androgen receptor modulator fast-track status, but CEO Mitchell Steiner told investors that the "compelling" results provide cause for hope that marketing clearance might be gained in Europe.